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DEAR EDITOR
Proton pump inhibitors (PPI) are the most 
commonly prescribed medications around the 
world globally, are highly potent gastric acid 
suppressors, currently approved by the US Food 
and Drug Administration for the management of 
a variety of gastrointestinal disorders including 
peptic ulcers, gastroesophageal reflux disease 
(GERD), eradication of Helicobacter pylori 
(in combination with antibiotics) as well as for 
the prevention of primary or recurrent peptic 
ulcers in  individuals exposed to aspirin or non- 
steroidal anti-inflammatory drugs (NSAIDS) 
or with Zollinger-Ellision syndrome (a gastrin-
secreting pancreatic tumor) (1). Gastric cancer is 
the fourth most predominant cancer and it is the 
second leading cause of cancer-related mortality 
around the globe. It is also considered as a lethal 
disease that hugely affects the economic, social, 
psychological and physical aspects of the patients 
(2). 
Though PPIs have been introduced in 1989, 
their correlation with gastric cancer has not 
been studied eminently yet ). However, majority 
of the literature review suggests a substantial 
risk of gastric cancers to be associated with 
PPI (1-3). The commonly proposed underlying 
mechanism is in close association with a 
study conducted 30 years ago, which reported 
excessive inhibition of gastric acid secretion in 
rodents with secondary hypergastrinemia leading 
to enterochromaffin-like-cell (ECL) hyperplasia 
(1, 4). Moreover, histopathological changes 
(such as hyperproliferation of gastric mucosa, 
replacement of normal mucosal glands with 
intestinal glands), loss of physiologic defense 
due to blocked gastric acid secretion, leads to 
chronic inflammation and bacterial colonization, 
and hence can ultimately cause gastric cancers 
(1). However, in contrast to other studies, two 
meta-analyses found no association between 
long-term use of PPI and any malignant changes 
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in the gastric mucosa (1). 
Overall, based on insufficient literature, we can 
conclude that the safety of PPI can be challenged 
considerablyand hence, complications of 
taking PPI should be taken seriously and more 
comprehensively designed and well-conducted 
randomized controlled trials with a long-
term follow-up should be conducted. These 
improvements can significantly decrease the 
chances of bias while evaluating the long-
term effects of PPI on gastric mucosa.In a 
country like Pakistan, where the health care is 
underperforming and there is inadequate patient 
follow up, it is startling to see the excessive use 
of PPI, both in tertiary care hospitals as well as 
in clinics. A study reports that patients are taking 
high doses of PPI for months and years without 
any clinical recommendation and follow-ups. 
Hence, in such developing countries it is not only 
a huge economic burden on the healthcare but is 
also associated with a life-threatening correlation 
of gastric cancer (5). Therefore, drugs alternative 
to PPI, with no complicated side effects, should 
be strongly encouraged. Physicians should 
inform their patients about its long-term side-
effects and also about avoiding any misuse.
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